妊娠期HIV感染女性替诺福韦艾拉酚胺血浆浓度降低:PANNA网络数据
该研究纳入欧洲20例妊娠期HIV感染女性,在妊娠晚期和产后进行密集药代动力学采样。妊娠晚期替诺福韦艾拉酚胺(TAF)的AUClast和Cmax几何均值较产后分别降低46%和52%,替诺福韦(TFV)的AUC0-24h、Cmax和Ctrough分别降低33%、30%和34%。妊娠晚期TAF AUClast低于53.1 ng∗h/mL的比例为6%,产后为0%;20例中1例妊娠晚期病毒载量>50 copies/mL,未发生母婴传播。
要点
- 妊娠晚期TAF的AUClast和Cmax几何均值较产后分别降低46%和52%。
- 妊娠晚期TFV的AUC0-24h、Cmax和Ctrough较产后分别降低33%、30%和34%。
- 妊娠晚期TAF AUClast低于53.1 ng∗h/mL的比例为6%,产后为0%。
核心结论
- 妊娠晚期HIV感染女性TAF血浆浓度约降低一半,但多数孕妇仍高于预设疗效目标。
- 妊娠晚期TFV浓度约降低30%,尽管暴露量下降,本研究观察到高病毒学疗效。
研究设计与样本
- 研究纳入来自欧洲各治疗中心的妊娠期HIV感染女性,在妊娠晚期和产后进行密集药代动力学采样。
- 采用非房室分析测定TAF和TFV的药代动力学参数,并报告临床疗效和安全性结局参数。
主要发现
- 共纳入20例妊娠期HIV感染女性。
- 妊娠晚期TAF AUClast和Cmax几何均值较产后分别降低46%和52%。
- 妊娠晚期TFV AUC0-24h、Cmax和Ctrough较产后分别降低33%、30%和34%。
- 妊娠晚期TAF AUClast<53.1 ng∗h/mL的比例为6%,产后为0%。
- 20例中1例妊娠晚期病毒载量>50 copies/mL,未发生母婴传播。
关键数值与推荐
- TAF AUClast的预设疗效目标为53.1 ng∗h/mL。
- 妊娠晚期TAF AUClast低于53.1 ng∗h/mL的比例为6%,产后为0%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Tenofovir alafenamide (TAF), a prodrug of tenofovir (TFV), is included in the majority of the recommended first-line antiretroviral regimens for patients living with human immunodeficiency virus (HIV), but there are limited data on TAF use in pregnant women. We aimed to examine the plasma pharmacokinetics of TAF and TFV in pregnant women from Europe. METHODS: Pregnant women living with HIV were included from treatment centers across Europe, and intensive pharmacokinetic sampling in the third trimester and postpartum was performed. Pharmacokinetic parameters of TAF and TFV were determined with noncompartmental analysis. The proportion of women with a TAF area under the curve (AUClast) below the target of 53.1 ng∗h/mL was determined. Clinical efficacy and safety outcome parameters were reported. RESULTS: In total, 20 pregnant women living with HIV were included. At the third trimester, geometric mean TAF AUClast and Cmax were decreased by 46% and 52%, respectively, compared with postpartum. TFV AUC0-24h, Cmax, and Ctrough decreased by 33%, 30%, and 34%, respectively. The proportion of women with a TAF AUClast < 53.1 ng∗h/mL was 6% at third trimester and 0% postpartum. One out of 20 women had a viral load > 50 copies/mL at third trimester and no mother-to-child transmission occurred. CONCLUSIONS: TAF plasma concentrations were reduced by about half in women living with HIV during third trimester of pregnancy but remained above the predefined efficacy target in the majority of the pregnant women. TFV concentrations were reduced by approximately 30% during third trimester. Despite the observed exposure decrease, high virologic efficacy was observed in this study.
引用
- Bukkems VE, Necsoi C, Hidalgo Tenorio C, et al. Tenofovir Alafenamide Plasma Concentrations Are Reduced in Pregnant Women Living With Human Immunodeficiency Virus (HIV): Data From the PANNA Network. Clin Infect Dis. 2022. PMID: 34864950. doi:10.1093/cid/ciab1010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。